Barclays analyst Balaji Prasad reiterated a Buy rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at $5.31.
Prasad covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, Coherus Biosciences, and Idexx Laboratories. According to TipRanks, Prasad has an average return of 3.5% and a 47.15% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $19.88 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $56.78 million and a GAAP net loss of $141.18 million. In comparison, last year the company earned a revenue of $29.02 million and had a GAAP net loss of $84.69 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics (RVNC) Company Description:
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
Read More on RVNC:
